AMANDA JEZEK

Antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR Act-S. 2076/H.R. 3932), Verifying Accurate Leading Edge IVCT Development (S. 2209/HR. 4128), PREVENT Pandemics Act, (PASTEUR Act-S.1355 /H.R. 2940), FDA proposed regulations regarding laboratory developed tests, House Energy and Commerce NIH RFI, CURES 2.0 RFI, avian flu outbreak (generally, no specific bill)

Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Center for Disease Control and Prevention, National Institutes of Health, Health Resources Services Administration, Food and Drug and Administration, and global programs for various infectious diseases related issues. Emergency supplemental funding support to address the COVID-19 pandemic and the monkeypox outbreak, FY2025 President's Budget, FY2025 Labor, Health, and Human Services Appropriations bills, FY2025 State and Foreign Operations Appropriations bills, FY2026 President's Budget, avian flu outbreak (generally, no specific bill)

Infectious diseases (generally, no specific legislation); antimicrobial (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza (generally, no specific legislation); public health security and bio-defense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White Care Act (generally, no specific legislation); Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR);HIV Epidemic Loan Repayment Program (HELP) Act(H.R. 2295) Verifying Accurate Leading Edge IVCT Development (VALID Act HR 3128/S.2209), Infectious diseases and bio-preparedness health professionals loan repayment issues, BIO Preparedness Workforce Act (S.3244/H.R.5602), Monkeypox outbreak and response (generally, no specific information), PHE Outbreak Activation Act (not-yet introduced), PREVENT Pandemics Act, Preparing for All Hazards and Pathogens Reauthorization Act (HR 4421), Pandemics and All-Hazards Preparedness and Response Act (S.2333), ID incentive payments (no specific information or bill numbers), CMS Medicare Physician Fee Schedule, avian flu (generally, no specific bill)

Antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR Act-S. 2076/H.R. 3932), Verifying Accurate Leading Edge IVCT Development (S. 2209/HR. 4128), PREVENT Pandemics Act, (PASTEUR Act-S.1355 /H.R. 2940), FDA proposed regulations regarding laboratory developed tests, House Energy and Commerce NIH RFI, CURES 2.0 RFI

Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Center for Disease Control and Prevention, National Institutes of Health, Health Resources Services Administration, Food and Drug and Administration, and global programs for various infectious diseases related issues. Emergency supplemental funding support to address the COVID-19 pandemic and the monkeypox outbreak, FY2025 President's Budget, FY2025 Labor, Health, and Human Services Appropriations bills, FY2025 State and Foreign Operations Appropriations bills, FY2026 President's Budget, avian flu outbreak

Infectious diseases (generally, no specific legislation); antimicrobial (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza (generally, no specific legislation); public health security and bio-defense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White Care Act (generally, no specific legislation); Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR);HIV Epidemic Loan Repayment Program (HELP) Act(H.R. 2295) Verifying Accurate Leading Edge IVCT Development (VALID Act HR 3128/S.2209), Infectious diseases and bio-preparedness health professionals loan repayment issues, BIO Preparedness Workforce Act (S.3244/H.R.5602), Monkeypox outbreak and response (generally, no specific information), PHE Outbreak Activation Act (not-yet introduced), PREVENT Pandemics Act, Preparing for All Hazards and Pathogens Reauthorization Act (HR 4421), Pandemics and All-Hazards Preparedness and Response Act (S.2333), ID incentive payments (no specific information or bill numbers), CMS Medicare Physician Fee Schedule, avian flu outbreak (generally, no specific bill)

INFECTIOUS DISEASES SOCIETY OF AMERICA

INFECTIOUS DISEASES SOCIETY OF AMERICA

INFECTIOUS DISEASES SOCIETY OF AMERICA

INFECTIOUS DISEASES SOCIETY OF AMERICA

INFECTIOUS DISEASES SOCIETY OF AMERICA